This company seems to have been delisted
Reason: Acquired by Novo Holdings
Last recorded trade on: February 19, 2025
Source: https://www.catalent.com/catalent-news/novo-holdings-completes-acquisition-of-catalent/
Reason: Acquired by Novo Holdings
Last recorded trade on: February 19, 2025
Source: https://www.catalent.com/catalent-news/novo-holdings-completes-acquisition-of-catalent/
Catalent
CTLT
HK$498.27
Share price
0.00%
Change (1 day)
14.32%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
Revenue for Catalent (CTLT)
Revenue in 2024 (TTM): HK$34.51 Billion
According to Catalent's latest financial reports the company's current revenue (TTM 
) is HK$34.70 Billion. In 2023 the company made a revenue of HK$32.00 Billion a decrease over the revenue in the year 2022 that were of HK$37.16 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Catalent from 2013 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | HK$34.51 B | 7.84% |
| 2023 | HK$32.00 B | -13.89% |
| 2022 | HK$37.16 B | 6.32% |
| 2021 | HK$34.95 B | 30.14% |
| 2020 | HK$26.86 B | 26.38% |
| 2019 | HK$21.25 B | 9.1% |
| 2018 | HK$19.48 B | 8.44% |
| 2017 | HK$17.96 B | 22.2% |
| 2016 | HK$14.70 B | 3.4% |
| 2015 | HK$14.21 B | -0.73% |
| 2014 | HK$14.32 B | 2.22% |
| 2013 | HK$14.01 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | HK$5.24 B | -84.89% | 🇺🇸 USA |
 Aerie Pharmaceuticals AERI | HK$1.67 B | -95.16% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | HK$31.90 B | -8.08% | 🇮🇪 Ireland |
 Intercept Pharmaceuticals
ICPT | HK$2.49 B | -92.82% | 🇺🇸 USA |